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Background:  Fibroblast growth factor-2 (FGF-2) signaling plays a pivotal role in the development of pulmonary arterial hypertension 
(PAH).PD173074 is a potent FGF receptor 1 (FGFR-1) inhibitor that displays high activity and selectivity. The aim of this study was to 
investigate the effects of PD173074 on monocrotaline-induced PAH. We also evaluated whether FGFR-1 inhibition could attenuate bone 
morphogenetic protein type II receptor (BMPR-II) down-regulation.
methods:  PAH model was established by a single intraperitoneal injection of monocrotaline. And then a daily intraperitoneal injection 
of PD173074 (20 mg/kg) was administered from day 14 to day 28. Hemodynamic parameters, right ventricular hypertrophy index and 
morphometry were evaluated at day 28.
results:  The expression of FGF-2 and FGFR-1 was upregulated in lung tissue after monocrotaline injection, and it was accompanied by 
hemodynamic changes and pulmonary vascular remodeling. PD173074 treatment significantly ameliorated PAH and vascular remodeling 
(Figure A). It decreased ERK1/2 activation and rescued total Akt expression, leading to a reduction in both proliferation and apoptosis in the 
lung. Besides, PD173074 rescued the expression of BMPR-II (Figure B).
conclusion:  These results suggest that PD173074 can efficiently alleviate pulmonary arterial hypertension and it may be an useful option 
for PAH. Our data also suggest a role of FGF-2/BMP signaling interaction in PAH.
 
